Page 2 of Alembic Pharmaceuticals

The pharma company also reported that the growth in specialty segment was driven by Gynecology, Anti-Diabetic, Ophthalmology and Orthopedics.

Brimonidine Tartrate Ophthalmic Solution, 0.15% has an estimated market size of US$ 97 million for twelve months ending Dec 2022…

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Calquence Capsules, 100 mg, of AstraZeneca.

Alembic has a cumulative total of 179 ANDA approvals (157 final approvals and 22 tentative approvals) from the USFDA.

Alembic has received a cumulative total of 179 ANDA approvals (156 final approvals and 23 tentative approvals) from USFDA.

The capsules have an estimated market size of US$ 244 million for twelve months ending Sep 2022 according to IQVIA.

According to the pharma major, the ANDA was filed by Aleor Dermaceuticals Limited (Aleor) which was amalgamated with Alembic.

The drug is indicated for the management of Vasospastic Angina, Chronic Stable Angina (Classical Effort-Associated Angina), and hypertension.

India Business Growth for the quarter is on the back of exceptionally high market growth in Q2 FY 21-22, the…

Reportedly, Alembic has a cumulative total of 171 ANDA approvals (147 final approvals and 24 tentative approvals) from USFDA.